[go: up one dir, main page]

MX2009004681A - Composicion compleja de liberacion controlada que comprende bloqueadores del receptor de angiotensina ii e inhibidores de hmg-coa-reductasa. - Google Patents

Composicion compleja de liberacion controlada que comprende bloqueadores del receptor de angiotensina ii e inhibidores de hmg-coa-reductasa.

Info

Publication number
MX2009004681A
MX2009004681A MX2009004681A MX2009004681A MX2009004681A MX 2009004681 A MX2009004681 A MX 2009004681A MX 2009004681 A MX2009004681 A MX 2009004681A MX 2009004681 A MX2009004681 A MX 2009004681A MX 2009004681 A MX2009004681 A MX 2009004681A
Authority
MX
Mexico
Prior art keywords
composition
hmg
angiotensin
coa reductase
release
Prior art date
Application number
MX2009004681A
Other languages
English (en)
Inventor
Sung Wuk Kim
Sung Jun Soo
Young Gwan Jo
Ja Seong Koo
Jae Woon Son
Original Assignee
Hanall Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanall Pharmaceutical Co Ltd filed Critical Hanall Pharmaceutical Co Ltd
Publication of MX2009004681A publication Critical patent/MX2009004681A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe en la presente una composición farmacéutica de combinación de liberación retrasada por tiempo de retraso que comprende un bloqueador de receptor de angiotensina II y un inhibidor HMG-CoA-reductasa, así como un método de preparación de la misma. La composición se diseña en base a cronoterapia en la cual se administran ingredientes activos para que tengan diferentes tiempos de comienzo, tal que la liberación de cada ingrediente activo de la composición en el cuerpo se pueda retrasar por tiempo de retraso a una velocidad específica. También, la composición es muy efectiva para el tratamiento de hipertensión y prevención de complicaciones en pacientes que tienen síndromes metabólicos que muestran diabetes, obesidad, hiperlipidemia, enfermedad de arterias coronarias y similares. De manera más específica, la composición es un sistema de distribución de fármacos diseñado tal que la liberación de cada fármaco se controle a una velocidad específica, y pueda mostrar el efecto más ideal, cuando se absorbe en el cuerpo.
MX2009004681A 2006-10-30 2007-10-30 Composicion compleja de liberacion controlada que comprende bloqueadores del receptor de angiotensina ii e inhibidores de hmg-coa-reductasa. MX2009004681A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20060105617 2006-10-30
PCT/KR2007/005405 WO2008054123A1 (en) 2006-10-30 2007-10-30 Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors

Publications (1)

Publication Number Publication Date
MX2009004681A true MX2009004681A (es) 2009-08-19

Family

ID=39344436

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004681A MX2009004681A (es) 2006-10-30 2007-10-30 Composicion compleja de liberacion controlada que comprende bloqueadores del receptor de angiotensina ii e inhibidores de hmg-coa-reductasa.

Country Status (11)

Country Link
US (1) US8642083B2 (es)
EP (1) EP2086519B1 (es)
JP (1) JP5377317B2 (es)
KR (1) KR100985254B1 (es)
CN (2) CN102973942B (es)
AU (1) AU2007314795B2 (es)
CA (1) CA2664893C (es)
IL (1) IL198349A0 (es)
MX (1) MX2009004681A (es)
RU (1) RU2453307C2 (es)
WO (1) WO2008054123A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110212175A1 (en) * 2006-10-30 2011-09-01 Hanall Biopharma Co., Ltd. Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor
US20110123612A1 (en) * 2008-04-10 2011-05-26 Sung Wuk Kim Pharmaceutical preparation containing non-dihydropyridine calcium channel blocker and angiotensin-2 receptor blocker
WO2010021473A2 (ko) * 2008-08-19 2010-02-25 한올제약주식회사 약제학적 제제
ES2336755B1 (es) * 2008-10-07 2011-01-21 Activery Biotech, S.L. Procedimiento para la preparacion de combinaciones de valsartan y simvastatina.
CZ301299B6 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
JP5308788B2 (ja) * 2008-11-27 2013-10-09 興和株式会社 貼付剤
KR101248804B1 (ko) * 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제
EP2392318A1 (en) * 2010-05-21 2011-12-07 Laboratorios Liconsa, S.A. A pharmaceutical controlled release composition of losartan
CN102485228B (zh) * 2010-12-02 2015-06-10 鲁南制药集团股份有限公司 一种药物组合物及其用途
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
DK3272342T3 (da) 2011-03-23 2021-06-07 Ironshore Pharmaceuticals & Dev Inc Fremgangsmåder og sammensætninger til behandling af opmærksomhedsforstyrrelse
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
KR20200003219A (ko) * 2011-05-20 2020-01-08 아스트라제네카 유케이 리미티드 로수바스타틴 칼슘의 약학 조성물
ES2622893T3 (es) * 2011-12-09 2017-07-07 Tratamiento de la pared arterial mediante la combinación de un inhibidor del SRAA y un inhibidor de la HMG-CoA reductasa
KR20130074808A (ko) * 2011-12-16 2013-07-05 한올바이오파마주식회사 스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물
SG11201405198YA (en) * 2012-03-30 2014-09-26 Dae Woong Pharma Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
EP2977048A4 (en) * 2013-03-12 2017-04-26 LG Life Sciences Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
US10703825B2 (en) 2013-03-13 2020-07-07 Daicel Corporation Cellulose acetate with a low degree of substitution
KR101579656B1 (ko) * 2013-12-12 2015-12-22 가천대학교 산학협력단 프라바스타틴과 발사르탄을 포함하는 약학 조성물
WO2015093067A1 (ja) * 2013-12-20 2015-06-25 株式会社ダイセル 脂質代謝改善作用を有する栄養組成物
EP3130236B1 (en) * 2014-03-24 2020-08-05 Daicel Corporation Nutritional composition
KR20160095826A (ko) * 2015-02-04 2016-08-12 제이더블유중외제약 주식회사 피타바스타틴 또는 이의 약학적으로 허용 가능한 염 및 발사르탄 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
CN104739833A (zh) * 2015-02-16 2015-07-01 江苏欧信医药化工有限公司 含替米沙坦和瑞舒伐他汀钙的复方双层片剂及其制备方法
KR20170003459A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
CN105232556A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种坎地沙坦酯/瑞舒伐他汀复方制剂及其制备方法
CN105395551A (zh) * 2015-11-19 2016-03-16 哈尔滨圣吉药业股份有限公司 一种奥美沙坦酯/瑞舒伐他汀复方制剂及其制备方法
CN105232555A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法
EP4255495A4 (en) 2020-12-03 2025-10-08 Battelle Memorial Institute COMPOSITIONS OF POLYMERIC NANOPARTICLES AND DNA NANOSTRUCTURES AND METHODS FOR NON-VIRAL DELIVERY
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
WO1995026188A1 (en) * 1994-03-29 1995-10-05 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
WO2000025752A1 (en) * 1998-11-02 2000-05-11 Church, Marla, J. Multiparticulate modified release composition
RU2276997C2 (ru) * 1999-08-30 2006-05-27 Санофи-Авентис Дойчланд Гмбх Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений
JP2001078681A (ja) * 1999-09-07 2001-03-27 Hiraizumi Kashi Honpo:Kk 画像付食品
JP2001078686A (ja) * 1999-09-13 2001-03-27 Aoyama Sfe:Kk 各種抽出方法で抽出されたプロポリスの有効成分を全体的に利用する組成物とその製造方法
EP1275373A4 (en) 2000-04-17 2007-04-04 Astellas Pharma Inc DRUG DISPERSION SYSTEM FOR THE AVOIDANCE OF PHARMACOKINETIC INTERACTIONS BETWEEN ACTIVE SUBSTANCES AND METHODOLOGY THEREOF
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
DE10301371A1 (de) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
JP4675586B2 (ja) * 2004-06-23 2011-04-27 壽製薬株式会社 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
KR100582347B1 (ko) 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
WO2008010008A2 (en) * 2006-07-17 2008-01-24 Wockhardt Limited Cardiovascular combinations using rennin-angiotensin inhibitors

Also Published As

Publication number Publication date
JP2010508267A (ja) 2010-03-18
CN102973942A (zh) 2013-03-20
AU2007314795B2 (en) 2012-02-16
RU2453307C2 (ru) 2012-06-20
US20100074951A1 (en) 2010-03-25
EP2086519A1 (en) 2009-08-12
CA2664893C (en) 2015-01-27
CN101528204A (zh) 2009-09-09
CA2664893A1 (en) 2008-05-08
CN102973942B (zh) 2015-08-12
IL198349A0 (en) 2010-02-17
JP5377317B2 (ja) 2013-12-25
WO2008054123A1 (en) 2008-05-08
EP2086519A4 (en) 2009-12-23
KR20080039303A (ko) 2008-05-07
US8642083B2 (en) 2014-02-04
AU2007314795A1 (en) 2008-05-08
RU2009115452A (ru) 2010-12-10
EP2086519B1 (en) 2017-06-21
KR100985254B1 (ko) 2010-10-04
CN101528204B (zh) 2012-12-12

Similar Documents

Publication Publication Date Title
MX2009004681A (es) Composicion compleja de liberacion controlada que comprende bloqueadores del receptor de angiotensina ii e inhibidores de hmg-coa-reductasa.
WO2009134076A3 (ko) 방출성이 제어된 안지오텐신 - II - 수용체 차단제와 H M G - C o A 환원 효소 억제제의 복합제 조성물
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
MY153027A (en) Combined preparation for the treatment of cardiovascular diseases based on chronotheraphy theory
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
WO2008099397A3 (en) Compositions and methods for enhancing transmucosal delivery
WO2008049657A3 (de) Verwendung von (meth)acrylat-copolymeren in retard-arzneiformen zur verringerung des einflusses von ethanol auf die wirkstofffreisetzung
WO2007058990A3 (en) Therapy using cytokine inhibitors
MX2007004987A (es) Nuevas formulaciones de tabletas de liberacion modificada para inhibidores de bomba de protones.
TW200738228A (en) Neramexane modified release matrix tablet
WO2010090494A3 (ko) 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
WO2009104939A3 (ko) 약제학적 제제
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
MX2007005065A (es) Forma de dosis de tiempo de retraso de farmacos para la terapia de insomnio.
TWI368521B (en) A spontaneous pharmaceutical composition for treatment and prevention of proliferative diseases,uses and preparation thereof
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
WO2009104916A3 (ko) 심혈관계 질환 치료용 약제학적 제제
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
WO2011113000A8 (en) Novel ester containing compositions and methods
WO2009125944A3 (ko) 비디히드로피리딘계 칼슘 채널 차단제 및 안지오텐신-2 수용체 차단제를 포함하는 약제학적 제제
WO2009047505A3 (en) Dexanabinol with inhibitors of braf or mek for the treatment of melanoma
WO2009142421A3 (ko) 약제학적 제제

Legal Events

Date Code Title Description
FA Abandonment or withdrawal